Mankind Pharma Ltd
Incorporated in 1995, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations in various acute and chronic therapeutic areas and several consumer healthcare products.[1]
- Market Cap ₹ 90,093 Cr.
- Current Price ₹ 2,249
- High / Low ₹ 2,490 / 1,241
- Stock P/E 52.2
- Book Value ₹ 210
- Dividend Yield 0.00 %
- ROCE 22.4 %
- ROE 18.4 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- Stock is trading at 10.7 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2015 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|
3,334 | 5,865 | 6,214 | 7,782 | 8,749 | 9,946 | |
2,748 | 4,427 | 4,565 | 5,791 | 6,848 | 7,586 | |
Operating Profit | 586 | 1,438 | 1,649 | 1,991 | 1,902 | 2,361 |
OPM % | 18% | 25% | 27% | 26% | 22% | 24% |
76 | 122 | 183 | 210 | 141 | 252 | |
Interest | 2 | 23 | 21 | 60 | 46 | 29 |
Depreciation | 39 | 99 | 119 | 167 | 326 | 378 |
Profit before tax | 621 | 1,438 | 1,692 | 1,975 | 1,671 | 2,205 |
Tax % | 29% | 27% | 24% | 26% | 22% | |
445 | 1,056 | 1,293 | 1,453 | 1,310 | 1,759 | |
EPS in Rs | 219.33 | 25.72 | 31.59 | 35.78 | 32.00 | 43.12 |
Dividend Payout % | 0% | 0% | 24% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 14% |
TTM: | 18% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 8% |
TTM: | 46% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | 65% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 24% |
Last Year: | 18% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2015 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|
Equity Capital | 20 | 40 | 40 | 40 | 40 | 40 |
Reserves | 2,035 | 3,445 | 4,682 | 6,115 | 7,395 | 8,388 |
0 | 131 | 241 | 873 | 170 | 179 | |
968 | 1,449 | 1,397 | 2,080 | 2,080 | 2,490 | |
Total Liabilities | 3,022 | 5,065 | 6,360 | 9,108 | 9,686 | 11,098 |
316 | 1,600 | 1,664 | 3,588 | 4,251 | 4,666 | |
CWIP | 47 | 317 | 372 | 701 | 550 | 159 |
Investments | 959 | 829 | 1,512 | 1,109 | 1,346 | 2,041 |
1,700 | 2,319 | 2,811 | 3,709 | 3,538 | 4,233 | |
Total Assets | 3,022 | 5,065 | 6,360 | 9,108 | 9,686 | 11,098 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2015 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|
1,070 | 1,137 | 920 | 1,813 | ||
-436 | -1,222 | -1,369 | -1,052 | ||
-531 | -8 | 605 | -740 | ||
Net Cash Flow | 103 | -92 | 156 | 22 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2015 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|
Debtor Days | 22 | 33 | 19 | 18 | 24 |
Inventory Days | 166 | 175 | 243 | 265 | 188 |
Days Payable | 71 | 145 | 137 | 162 | 126 |
Cash Conversion Cycle | 117 | 63 | 125 | 121 | 85 |
Working Capital Days | 56 | 35 | 43 | 62 | 45 |
ROCE % | 37% | 32% | 22% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
10 May - Allotment of 46698 equity shares under Mankind Pharma Limited Employee Stock Option Plan 2022
- Intimation Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 9 May
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
8 May - The Company will host Investor Conference Call on Thursday, May 16, 2024 at 12:00 Noon (IST) for Q4FY24 and FY24.
- Board Meeting Intimation for Under Regulation 29 Of The SEBI (LODR) Regulations, 2015 8 May
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
3 May - Secretarial Compliance Report for the financial year ended March 31, 2024
Concalls
-
Feb 2024Transcript PPT
-
Jan 2024TranscriptNotesPPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
Jun 2023Transcript PPT
Leadership[1]
<h1>1 Rank in Prescriptions over the last 5 yrs.</h1> <h1>Youngest in Top 5 of the IPM</h1> <h1>4 By value in the IPM</h1> <h1>4 Consumer Healthcare brands Market ranked #1 in their categories</h1>